Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
Hans C. Lee, Saad Z. Usmani, Robert M. Rifkin, Dasha Cherepanov, Evangelos Terpos, Faith E. Davies, Dorothy Romanus, Antonio Palumbo, Aditya Raju, Jesus G. Berdeja, Dawn Marie Stull, Noemi Puig, Jorge Vela-Ojeda, Rafat Abonour, Xavier Leleu, Hui Huang, Ajai Chari, Eileen Farrelly, Mario Boccadoro, Gordon Cook, Katja Weisel, Gareth J. Morgan, Caitlin Costello, Jeffrey A. Zonder, Marlo Blazer, Michael A. Thompson, Roman Hájek
Publikováno v:
Annals of Hematology
Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights
Autor:
Saad Z. Usmani, Annette Lam, Bareng A. S. Nonyane, Eric M Maiese, Shaji Kumar, Brian G.M. Durie, Thierry Facon, Rachel Kobos, Eric M. Ammann
Publikováno v:
American Journal of Hematology
Daratumumab in combination with lenalidomide‐dexamethasone (D‐Rd) recently received FDA approval for the treatment of transplant‐ineligible patients with newly diagnosed multiple myeloma (NDMM). The present PEGASUS study compared progression‐
Autor:
Manisha Bhutani, Myra M. Robinson, Shebli Atrash, Jordan Robinson, Daniel Slaughter, Kristen Cassetta, Ami Ndiaye, Saad Z. Usmani, Barry Paul, Peter M. Voorhees
Publikováno v:
Blood. 136:11-13
Background: Targeting B-cell maturation antigen (BCMA) with antibody-drug conjugates (ADCs), bispecific antibodies, or chimeric antigen receptor t-cells (CAR-Ts) has proven safe and effective in recent clinical trials, but relapses remain common. As
Autor:
Faith E. Davies, Andrew Spencer, Jesus G. Berdeja, Jim Omel, Dorothy Romanus, Evangelos Terpos, Xavier Leleu, Dawn M Stull, Mario Boccadoro, Jorge Vela-Ojeda, Katja Weisel, Robert M. Rifkin, Gordon Cook, Saad Z. Usmani, Jeffrey A. Zonder, Caitlin Costello, Noemi Puig, Vania Hungria, Michael A. Thompson
Publikováno v:
Future Oncology
Future oncology (London, England), vol 15, iss 13
Future oncology (London, England), vol 15, iss 13
With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients’ outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of
Autor:
Ravi Vij, Shaji Kumar, Smith Giri, Saad Z. Usmani, Robert F. Cornell, Ankit Kansagra, Michaela Liedtke, Saurabh Chhabra, Luciano J. Costa, Yubin Kang, Kelly N. Godby, Susan Bal, Ehsan Malek, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S148-S149
Autor:
Martin Kaiser, Hans C. Lee, Saad Z. Usmani, Evangelos Terpos, Joseph Mikhael, Karthik Ramasamy, Maria-Victoria Mateos, Alessandra Larocca, Jennifer Elliott, Antonio Palumbo, Ajai Chari, Sonja Zweegman, Roman Hájek, Gordon Cook, Caitlin Costello, Katja Weisel
Publikováno v:
Blood cancer journal, vol 11, iss 2
Blood Cancer Journal
Terpos, E, Mikhael, J, Hajek, R, Chari, A, Zweegman, S, Lee, H C, Mateos, M V, Larocca, A, Ramasamy, K, Kaiser, M, Cook, G, Weisel, K C, Costello, C L, Elliott, J, Palumbo, A & Usmani, S Z 2021, ' Management of patients with multiple myeloma beyond the clinical-trial setting : understanding the balance between efficacy, safety and tolerability, and quality of life ', Blood cancer journal, vol. 11, no. 2, 40 . https://doi.org/10.1038/s41408-021-00432-4
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-13 (2021)
Blood Cancer Journal
Terpos, E, Mikhael, J, Hajek, R, Chari, A, Zweegman, S, Lee, H C, Mateos, M V, Larocca, A, Ramasamy, K, Kaiser, M, Cook, G, Weisel, K C, Costello, C L, Elliott, J, Palumbo, A & Usmani, S Z 2021, ' Management of patients with multiple myeloma beyond the clinical-trial setting : understanding the balance between efficacy, safety and tolerability, and quality of life ', Blood cancer journal, vol. 11, no. 2, 40 . https://doi.org/10.1038/s41408-021-00432-4
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-13 (2021)
© The Author(s) 2021.
Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, includ
Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd46f77dd0aa5874166b3d65eacf8ac7
https://eprints.whiterose.ac.uk/171668/6/s41408-021-00432-4.pdf
https://eprints.whiterose.ac.uk/171668/6/s41408-021-00432-4.pdf
Autor:
Sarah A. Holstein, Nizar Bahlis, P. Leif Bergsagel, Manisha Bhutani, Niccolo Bolli, Carrie Brownstein, Pierre Demolis, David Foureau, Francesca Gay, Irene M. Ghobrial, Nicole Gormley, Jens Hillengass, Martin Kaiser, Marcela V. Maus, J. Joseph Melenhorst, Maximilian Merz, Michael O. Dwyer, Bruno Paiva, Marcelo C. Pasquini, Nina Shah, Sandy W. Wong, Saad Z. Usmani, Philip L. McCarthy
Publikováno v:
Transplant Cell Ther
Transplantation and cellular therapy, vol 27, iss 10
Transplantation and cellular therapy, vol 27, iss 10
The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Sc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d79ec414d86fe8eb620dacd754421351
http://hdl.handle.net/2318/1791012
http://hdl.handle.net/2318/1791012
Autor:
Amarendra K. Neppalli, Sagar Lonial, Shaji Kumar, Sundar Jagannath, Jatin P. Shah, Mark A. Fiala, Paul G. Richardson, Joshua Mansour, Megan Jagosky, Ujjawal H. Gandhi, Zhubin Gahvari, Yubin Kang, Kelly N. Godby, Michaela Liedtke, Elizabeth McGehee, Ravi Vij, Xiwen Ma, David S. Siegel, Robert F. Cornell, Barry Paul, Ehsan Malek, William Varnado, Ankit Kansagra, Shijie Tang, Luciano J. Costa, Saad Z. Usmani, Emma C. Scott, Arjun Lakshman, Michael Kauffman, Noa Biran, Ridhi Gupta, Saurabh Chhabra, Saranya Kodali, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari, Sharon Shacham, Ajai Chari
Publikováno v:
American Journal of Hematology. 96
Autor:
Luciano J. Costa, Benjamin A. Derman, Susan Bal, Surbhi Sidana, Saurabh Chhabra, Rebecca Silbermann, Jing C. Ye, Gordon Cook, Robert F. Cornell, Sarah A. Holstein, Qian Shi, James Omel, Natalie S. Callander, Wee Joo Chng, Vania Hungria, Angelo Maiolino, Edward Stadtmauer, Sergio Giralt, Marcelo Pasquini, Andrzej J. Jakubowiak, Gareth J. Morgan, Amrita Krishnan, Graham H. Jackson, Mohamad Mohty, Maria Victoria Mateos, Meletious A. Dimopoulos, Thierry Facon, Andrew Spencer, Jesus San Miguel, Parameswaran Hari, Saad Z. Usmani, Salomon Manier, Phillip McCarthy, Shaji Kumar, Francesca Gay, Bruno Paiva
Publikováno v:
Leukemia. 35(1)
Minimal residual disease (MRD) assessment is incorporated in an increasing number of multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a determinant of subsequent therapy. There is substantial heterogeneity acros
Autor:
Jacob P. Laubach, Niels W.C.J. van de Donk, Tahamtan Ahmadi, Andrew Belch, Nizar J. Bahlis, Torben Plesner, Peter M. Voorhees, Clarissa M. Uhlar, Huaibao Feng, Paul G. Richardson, Sagar Lonial, Ming Qi, Jianping Wang, Brendan M. Weiss, Hareth Nahi, Saad Z. Usmani
Publikováno v:
Usmani, S Z, Nahi, H, Plesner, T, Weiss, B M, Bahlis, N J, Belch, A, Voorhees, P M, Laubach, J P, van de Donk, N W C J, Ahmadi, T, Uhlar, C M, Wang, J, Feng, H, Qi, M, Richardson, P G & Lonial, S 2020, ' Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma : final results from the phase 2 GEN501 and SIRIUS trials ', The Lancet Haematology, vol. 7, no. 6, pp. e447-e455 . https://doi.org/10.1016/S2352-3026(20)30081-8
The Lancet Haematology, 7(6), e447-e455. Lancet Publishing Group
The Lancet Haematology, 7(6), e447-e455. Lancet Publishing Group
Summary Background Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a pooled, post-hoc final analysis of these two studies. Methods GEN501 was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff9287699020810f638c78fcf43e906
https://research.vumc.nl/en/publications/2d5388d9-2ada-497b-a6e7-d98a23946662
https://research.vumc.nl/en/publications/2d5388d9-2ada-497b-a6e7-d98a23946662